MetaVia Inc. 8-K

What Happened
On May 27, 2026, MetaVia Inc. filed a Form 8-K under Regulation FD to announce a press release that the company is presenting new Phase 1 data for DA-1726, a novel dual oxyntomodulin (OXM) analog that targets GLP-1 receptors (GLP1R) and glucagon receptors (GCGR). The data are being presented as a late-breaking poster at the European Association for the Study of the Liver Congress (EASL 2026) in Barcelona, held May 27–30, 2026. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: May 27, 2026; event: EASL 2026 (May 27–30, Barcelona).
• Asset: DA-1726 — a dual OXM analog agonist targeting GLP1R and GCGR; Phase 1 clinical data being presented.
• Presentation: late-breaking poster session at a major scientific meeting (EASL).
• Disclosure: press release included as Exhibit 99.1 to the 8-K; information on websites is not incorporated into the filing.

Why It Matters
This filing signals an early clinical milestone for MetaVia—public release and scientific presentation of Phase 1 data for DA-1726 increases visibility of the program and provides investors with an update on clinical progress. Presenting at EASL, a major liver/hepatology congress, may draw attention from clinicians and potential partners. The 8-K is a Regulation FD disclosure, meaning the company made the information public; the filing does not include financial results or additional details about the data beyond the press release.